Expanded Access & Compassionate Use Policy

Cartography Biosciences is building a differentiated oncology pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics. We are committed to developing our medicines through rigorous clinical research in areas of unmet need. Currently, we do not offer expanded access to our investigational therapies outside of clinical trials. We believe that participation in clinical trials is the most appropriate and equitable pathway for patients until the safety and tolerability of an investigational therapy has been established and evaluated by regulatory authorities. We will update this policy if the status changes.

For more information about our ongoing studies, please visit clinicaltrials.gov and search “Cartography” to find our clinical trials that may be recruiting. If you are a healthcare professional and would like more information on our investigational therapies please send an inquiry to clinicaltrials@cartography.bio. Information about FDA’s expanded access program is available through their website.